Acute lymphoblastic leukaemia trials in Ireland
6 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleInterfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
- Where
- Dublin
- Age
- 1 day to 1 year
- People
- 160 worldwide
- Run by
- Princess Maxima Center for Pediatric Oncology
See details and how to joinNCT05327894 · EU 2022-502503-30-00 - Phase 3Taking peopleA Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
- Where
- Cork, Dublin, Dublin 8, Galway
- Age
- 0 years to 45 years
- People
- 6,430 worldwide
- Run by
- Mats Heyman
See details and how to joinNCT04307576 · EU 2022-501050-11-01 - Phase 1/2Taking peopleInotuzumab ozogamicin for Acute Lymphoblastic Leukemia
- Where
- Dublin
- Age
- Up to 17 years
- People
- 142 worldwide
- Run by
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
See details and how to join2023-504694-20-00 · EU 2023-504694-20-00 - Phase 1/2Taking peopleHEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies
- Where
- Dublin
- Age
- 1 year to 21 years
- People
- 26 worldwide
- Run by
- Princess Maxima Center for Pediatric Oncology
See details and how to joinNCT05658640 · EU 2022-501869-41-00 - Phase 1/2Taking peopleHEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
- Where
- Dublin
- Age
- 1 year to 21 years
- People
- 26 worldwide
- Run by
- Princess Maxima Center for Pediatric Oncology
See details and how to joinNCT05745714 · EU 2022-501867-42-01 - Phase 1/2Taking peopleHEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
- Where
- Dublin
- Age
- 1 year to 21 years
- People
- 26 worldwide
- Run by
- Princess Maxima Center for Pediatric Oncology
See details and how to joinNCT05751044 · EU 2022-501866-22-00